Navigation Links
BeneChill Launches European Study of Intra-Arrest Cooling
Date:2/3/2009

SAN DIEGO, Feb. 3 /PRNewswire/ -- BeneChill, Inc. (www.benechill.com) today announced the start of the PRINCE (Pre-Resuscitation Intra-Nasal Cooling Effectiveness) study. This randomized study will determine whether intra-nasal cooling using BeneChill's RhinoChill device during resuscitation increases patient resuscitation and survival rates.

The PRINCE study is being conducted as a post-market approval study in Europe. The company received CE marking for the RhinoChill system in 2007.

The non-invasive, portable, and easy-to-use RhinoChill Device is used without external power for rapid therapeutic patient cooling. This system uses a nasal catheter to deliver a proprietary inert coolant to the nasal cavity to reduce temperature in clinically indicated conditions. Current uses of cooling technologies include ischemic events such as cardiac arrest, stroke, and traumatic brain injury. Unlike other cooling devices, the RhinoChill device is easily utilized in emergency field settings.

As part of the upcoming study, patients will receive either advanced cardiac life support measures (ACLS) alone or ACLS supplemented by intra-nasal cooling. The study will be conducted in Belgium, Germany, Italy and Sweden over the next 6-9 months.

"Out-of-hospital cardiac arrest is a significant cause of death," said BeneChill founder/CEO Denise Barbut, MD MRCP. "Mild hypothermia induced after resuscitation from cardiac arrest has been shown to improve survival in humans. Given that our team previously demonstrated the cooling efficacy of our technology in clinical trials around the globe, the PRINCE study is the next logical step."

BeneChill COO Allan Rozenberg, PhD, noted at today's announcement: "Earlier initiation of cooling in animals has a great impact on their survival. In randomized pig studies, for example, we've seen dramatically higher survival rates when intra-nasal cooling has been initiated during resuscitation."

"The RhinoChill Device uses the nasal cavity for cooling," Dr. Rozenberg stressed, noting "This is advantageous since the nasal cavity allows easy access into the body, is in close proximity to the brain, and is a natural heat exchanger."

About BeneChill

BeneChill is a venture capital funded medical device company based in San Diego, CA. The company is developing products in the therapeutic hypothermia arena with a focus on rapid, non-invasive cooling for use in the field. The RhinoChill System is an investigational device in the United States, and is limited by US law to investigational use only.


'/>"/>
SOURCE BeneChill
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BeneChills RhinoChill System Receives CE Marking for European Commercial Sale
2. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
3. UPMC Health Plan Launches New Personal Health Record
4. HealthInsuranceFinders.com Launches Video Contest for Young Directors
5. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
6. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
7. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
8. Mannatech Launches Phase One of New Sales and Training Tools
9. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
10. Actavis Launches Carvedilol Tablets in the U.S.
11. MedQuist Re-launches New, Improved Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health ... Distinction, recognizing the organization as a top behavioral service provider in the country. ... clinical quality, staff satisfaction and qualifications, and consumer satisfaction. These areas are measured ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation ... research and development, largely due to its potential for revolutionizing human disease treatment. ... and human induced pluripotent stem cells (hiPSCs). , Both platforms have distinct ...
(Date:12/6/2016)... ... December 06, 2016 , ... METTLER TOLEDO has ... knowledge resources, including white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, ... more than 9,000 documents, webinars and videos available online, visit the METTLER ...
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... EHS audit protocols to understand the scope of their EHS regulatory obligations and ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Nov. 29, 2016 Several leading Alzheimer,s ... Accera, Inc. at 11 a.m. EST on ... Conference on Clinical Trials for Alzheimer,s Disease (CTAD). The ... in Alzheimer,s disease and therapeutic targets that address deficient ... "Following the recent failure of another therapy targeting the ...
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, ... Commercialization of Public Research (the Florida Institute) ... agreement SegAna, LLC, an Orlando ... Central Florida. The Florida Institute supports new company ... funding gaps for companies spinning out of Florida-based universities ...
(Date:12/5/2016)... According to a new market research report "Cartilage Repair/ Cartilage ... Scaffolds, Cell-free composites), Application (Hyaline Cartilage, Fibrocartilage), by Region - Forecast ... USD 779.8 Million by 2021 from USD 414.6 Million in 2016, ... 2016 to 2021. Continue Reading ... ...
Breaking Medicine Technology: